Project Grant HT94252410850
Award Date 8/1/24
Completion Date 7/31/27
Dollars Obligated $846K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15260, USA
Similar Awards
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $346,319.00 to the University of Pittsburgh to conduct research on "INTRAGENIC REARRANGEMENT BURDEN AS A GENOMIC PREDICTOR OF IMMUNOTHERAPY BENEFIT IN TRIPLE-NEGATIVE BREAST CANCER." The award period runs from August 1, 2024 to July 31, 2027. The University of Pittsburgh, a major public research university, will leverage its expertise in...
- This Project Grant award, worth $647,861.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Pittsburgh. The funding will support a 3-year research project evaluating the interplay between B-cells and T-cells within the tumor microenvironment of melanoma, and the impact on immune checkpoint blockade therapies. The University of Pittsburgh, a major recipient of federal biomedical research grants, will...
- The University of Pittsburgh has been awarded a $681,379 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to evaluate B-T cell cross talk within tertiary lymphoid structures in melanoma progression and immune checkpoint blockade. The award has a performance period from July 1, 2024 to June 30, 2027. This research project aims to enhance understanding of the immune processes involved in melanoma development and response to...
- This $726,989 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of Pittsburgh on immunotherapeutic targeting of SLC39A9 in CDKN2A-low melanoma. The research aims to develop novel diagnostic tools, therapeutic interventions, and clinical practice guidelines to address critical health challenges relevant to military personnel. The project will span 3 years, from September 2025...
- This federal Project Grant award of $4,902,315.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports a research project titled "UNDERSTANDING THE EFFECTS OF INTRACAVITARY CONDITIONING IN BREAST CANCER METASTATIC TO THE PLEURA OR THE PERITONEUM" at the University of Pittsburgh. The project aims to conduct advanced biomedical research focused on developing innovative medical solutions to address critical health challenges relevant to...
- The University of Pittsburgh was awarded a $712,770 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The three-year grant will fund research into the role of RUNX1 rearrangements in triple-negative breast cancer progression and immune evasion. Through September 2025, the University will investigate medical solutions for aggressive breast cancers that lack estrogen receptors, progesterone receptors, and excess HER2...
- This $1,264,474 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the University of Pittsburgh's research on "Molecular Insights into Immune Suppression in Kidney Cancer and Novel Therapeutic Opportunities". The grant, effective September 1, 2024 through August 31, 2028, will fund the university's investigations into improving understanding of immune system mechanisms involved in kidney cancer and...
- This Project Grant award of $1,749,000.00 from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research at the University of Pittsburgh on the "Therapeutic Implications of TNBC-Specific ETV6 Rearrangements: Chemoresistance and Immune Evasion". The project aims to investigate mechanisms of chemoresistance and immune evasion in triple-negative breast cancer with ETV6 rearrangements, with the goal of...
- The University of Pittsburgh was awarded a $1,144,800 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research aimed at overcoming immunotherapy resistance in acral melanoma. The research, which will take place over 3 years from September 1, 2025 to August 31, 2028, seeks to transform healthcare for military service members and the broader public by developing novel diagnostic tools, therapeutic interventions, and clinical...
- This federal Project Grant award of $1,183,560 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of Pittsburgh to overcome immunotherapy resistance in acral melanoma. The grant will fund a multi-year research project aimed at developing novel diagnostic tools and therapeutic interventions to address this critical health challenge relevant to military personnel. The university's robust research...